Agios Pharmaceuticals | AGIO - Ebitda


Agios Pharmaceuticals reported $-125.8M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
AbbVie USD 4.34B 56M Jun/2025
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Amgen USD 5.91B 2.31B Sep/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
Astellas Pharma JPY 151.7B 11.36B Sep/2025
AstraZeneca USD 4.96B 127M Jun/2025
Bayer EUR 1.51B 1.28B Sep/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Exelixis USD 248.93M 28.02M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
Incyte USD 581.52M 358.87M Jun/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -208M 552M Sep/2025
Novartis USD 5.88B 290M Sep/2025
Novartis USD 5.84B 235M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025